These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17371250)

  • 1. Chemically targeting the PI3K family.
    Knight ZA; Shokat KM
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):245-9. PubMed ID: 17371250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
    Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
    Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of class II phosphoinositide 3-kinase in cell signalling.
    Falasca M; Maffucci T
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):211-4. PubMed ID: 17371240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
    Elis W; Triantafellow E; Wolters NM; Sian KR; Caponigro G; Borawski J; Gaither LA; Murphy LO; Finan PM; Mackeigan JP
    Mol Cancer Res; 2008 Apr; 6(4):614-23. PubMed ID: 18403640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
    Van Aller GS; Carson JD; Fernandes C; Lehr R; Sinnamon RH; Kirkpatrick RB; Tummino PJ; Luo L
    Anal Biochem; 2008 Dec; 383(2):311-5. PubMed ID: 18814837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
    Boller D; Schramm A; Doepfner KT; Shalaby T; von Bueren AO; Eggert A; Grotzer MA; Arcaro A
    Clin Cancer Res; 2008 Feb; 14(4):1172-81. PubMed ID: 18281552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
    van der Merwe JQ; Moreau F; MacNaughton WK
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Hood J; Soll R
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):204-6. PubMed ID: 17371238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
    Wee S; Lengauer C; Wiederschain D
    Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential roles of phosphatidylinositol 3-kinase/akt pathway in retinal ganglion cell survival in rats with or without acute ocular hypertension.
    Huang Y; Cen LP; Luo JM; Wang N; Zhang MZ; van Rooijen N; Pang CP; Cui Q
    Neuroscience; 2008 Apr; 153(1):214-25. PubMed ID: 18358617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taming the PI3K team to hold inflammation and cancer at bay.
    Hirsch E; Ciraolo E; Ghigo A; Costa C
    Pharmacol Ther; 2008 May; 118(2):192-205. PubMed ID: 18420279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
    Sturgeon SA; Jones C; Angus JA; Wright CE
    Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K inhibitors for cancer treatment: where do we stand?
    Maira SM; Stauffer F; Schnell C; García-Echeverría C
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):265-72. PubMed ID: 19143644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis.
    Hawkins PT; Stephens LR
    Science; 2007 Oct; 318(5847):64-6. PubMed ID: 17916723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal cell-derived factor 1-alpha (SDF)-induced human T cell chemotaxis becomes phosphoinositide 3-kinase (PI3K)-independent: role of PKC-theta.
    Shahabi NA; McAllen K; Sharp BM
    J Leukoc Biol; 2008 Mar; 83(3):663-71. PubMed ID: 18055570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.